NASDAQ:CRBP

Corbus Pharmaceuticals Q2 2026 Earnings Results & Report

Corbus Pharmaceuticals logo
$2.06 -0.37 (-15.23%)
Closing price 04:00 PM Eastern
Extended Trading
$2.05 -0.01 (-0.49%)
As of 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corbus Pharmaceuticals missed analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$1.81 versus the -$1.26 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Corbus Pharmaceuticals EPS Results

Actual EPS
-$1.81
Consensus EPS
-$1.26
Beat/Miss
Missed by -$0.55
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Corbus Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Corbus Pharmaceuticals Q2 2026 Earnings FAQ

Corbus Pharmaceuticals (NASDAQ:CRBP) reported earnings of -$1.81 per share for Q2 2026, missing the consensus estimate of -$1.26. The report was announced on Thursday, August 6, 2026.

Corbus Pharmaceuticals Earnings Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
Corbus Pharmaceuticals Reports Positive Oral Obesity Drug Data
See More Corbus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Corbus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your email.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals (NASDAQ:CRBP) is a clinical-stage biotechnology company based in Norwood, Massachusetts. It develops investigational medicines, with current research focused on cancer and obesity.

Its oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, and CRB-601, an antibody targeting the αvβ8 integrin. The company is also developing CRB-913, an investigational drug candidate designed to act on the cannabinoid CB1 receptor for obesity treatment. These candidates are in development and are not approved medicines.

Founded in 2014, Corbus previously focused on inflammatory and fibrotic diseases before shifting its research toward oncology and metabolic disorders. The company is led by co-founder and Chief Executive Officer Yuval Cohen.

View Corbus Pharmaceuticals Profile